{"doi":"10.2147/ndt.s90796","title":"Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study","abstract":null,"journal":"Neuropsychiatric Disease and Treatment","year":2015,"id":600015,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1538013,"name":"Won-Myong Bahk","orcid":null,"position":1,"is_corresponding":false},{"id":1538014,"name":"Young Sup Woo","orcid":null,"position":2,"is_corresponding":false},{"id":1538015,"name":"Kyung-Uk Lee","orcid":null,"position":3,"is_corresponding":false},{"id":754958,"name":"Do Hoon Kim","orcid":"0000-0002-7187-3306","position":4,"is_corresponding":false},{"id":1538016,"name":"Moon-Doo Kim","orcid":"0000-0002-6441-630X","position":5,"is_corresponding":false},{"id":582227,"name":"Won Kim","orcid":"0000-0003-3423-3825","position":6,"is_corresponding":false},{"id":1538017,"name":"Jong-Chul Yang","orcid":null,"position":7,"is_corresponding":false},{"id":1538018,"name":"Kwang Heun Lee","orcid":null,"position":8,"is_corresponding":false},{"id":1538012,"name":"Jong-Hyun Jeong","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study","abstract":"OBJECTIVES: The primary aim of this non-inferiority study was to investigate the clinical effectiveness and safety of generic escitalopram (Lexacure(®)) versus branded escitalopram (Lexapro(®)) for patients with major depressive disorder (MDD). METHODS: The present study included 158 patients, who were randomized (1:1) to receive a flexible dose of generic escitalopram (n=78) or branded escitalopram (n=80) over a 6-week single-blind treatment period. The clinical benefits in the two groups were evaluated using the Montgomery-Åsberg Depression Rating Scale (MADRS), the 17-item Hamilton Depression Rating Scale (HDRS), the Clinical Global Impressions-Severity scale (CGI-S), and the Clinical Global Impressions-Improvement scale (CGI-I) at baseline, week 1, week 2, week 4, and week 6. The frequency of adverse events (AEs) was also assessed to determine safety at each follow-up visit. RESULTS: During the 6-week study period, 30 patients (38.5%) from the generic escitalopram group and 28 patients (30.0%) from the branded escitalopram group dropped out of the study (P=0.727). The MADRS, HDRS, CGI-S, and CGI-I scores significantly decreased in both groups, and there were no significant differences between the groups. At week 6, 28 patients (57.1%) in the generic escitalopram group and 35 patients (67.3%) in the branded escitalopram group had responded to treatment (as indicated by a ≥50% decrease from the baseline MADRS score; P=0.126), and the remission rates (MADRS score: ≤10) were 42.9% (n=21) in generic escitalopram group and 53.8% (n=28) in the branded escitalopram group (P=0.135). The most frequently reported AEs were nausea (17.9%), sleepiness/somnolence (7.7%), weight gain (3.8%), and dry mouth (2.6%) in the generic escitalopram group and nausea (20.0%), sleepiness/somnolence (3.8%), weight gain (2.5%), and dry mouth (2.5%) in the branded escitalopram group. CONCLUSION: The present non-inferiority study demonstrated that generic escitalopram is a safe and an effective initial treatment for patients with MDD and may also be considered as an additional therapeutic option for this population.","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26504387","pmcid":"PMC4605251","openalex_id":"https://openalex.org/W1957941398","authors":[],"funders":[],"total_grants":0,"fwci":0.2791,"citation_percentile":0.65669263,"influential_citations":0,"citation_trend":[{"year":2018,"count":1},{"year":2020,"count":1},{"year":2023,"count":1},{"year":2025,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.dovepress.com/getfile.php?fileID=27452","host_type":"journal"},{"url":"https://www.dovepress.com/getfile.php?fileID=27452","host_type":"GOLD"},{"url":"https://www.dovepress.com/getfile.php?fileID=27452","host_type":"publisher"},{"url":"https://doi.org/10.2147/ndt.s90796","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26504387","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4605251","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC4605251","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC4605251?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Treatment of Major Depression","Pharmaceutical Economics and Policy","Pharmaceutical industry and healthcare","Medicine"],"mesh_terms":[],"keywords":["Escitalopram","Medicine","Rating scale","Major depressive disorder","Depression (economics)","Internal medicine","Adverse effect","Randomized controlled trial","Psychiatry","Clinical trial","Hamilton Rating Scale for Depression","Psychology","Antidepressant","Depression","Branded Escitalopram","Lexapro®","Generic Escitalopram","Lexacure®"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T11:59:57.232767Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}